Pfizer is partnering with oncology services company Crown Bioscience to develop novel therapeutics for cancers prevalent in Asia. The joint research will be carried out at Crown’s new facility near Shanghai and aims to discover and advance multiple candidates for clinical development.
Crown will receive an upfront payment and research funding under the terms of the deal with Pfizer. It is also eligible to preclinical and development milestones as products progress.
Based in California, Crown operates wholly owned research facilities at campuses in Beijing and Taicang, China, and in Indianapolis. The company claims its CrystalClear™ and HuPrime™ platforms provide unique capabilities in lead optimization and translational oncology for the development of clinical candidates.